Intravenous Immune Globulin: Adverse Effects
UptoDate June, Perez, E.E. & Silvergleid, A.J., 2017
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
Reversible Anorgasmia With Topiramate Therapy for Migraine
Neurol 65:1333-1334, Newman,L.C.,et al, 2005
Stroke-Like Migraine Attacks After Radiation Therapy Syndrome
Neurol 104:e210203, Lubotzky,A.,t al, 2025
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Cyclic Vomiting Syndrome in Children
AJGH 2:doi:10.33552/AJGH.2020, Al-Ansari, N., 2020
Acute Treatment of Migraine in Children and Adolescents
Neurol 93:487-499, Oskoui, M.,et al, 2019
Migraine
NEJM 377:553-561, Charles, A., 2017
Risk Development of Medication Overuse Headache With Nonsteroidal Anti-inflammatory Drug Therapy for Migraine A Critically Appraised Topic
The Neurologist 17:297-299, Starling, A.J.,et al, 2011
Differential Features of Carotid and Vertebral Artery Dissections
Neurol 77:1174-1181, Debette, S.,et al, 2011
Headache in Transplant Patients
www.medlink.com, Aug, Lai, T.H., 2011
Hemorrhagic Manifestations of Reversible Cerebral Vasoconstriction Syndrome: Frequency, Features, and Risk Factors
Stroke 41:2505-2511, 2455, Ducros,A.,et al, 2010
Differential Diagnosis of Postpartum Headaches
Rev Mex Anest 32:Suppl1 S16-S23, MacArthur,A., 2009
Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts & Leukoencephalopathy (CADASIL)
UpToDate (www.uptodate.com) Aug 21, Dichgans,M.,et al., 2007
Recent Advances in the Diagnosis and Management of Migraine
BMJ 332:25-29, Goadsby,P.J., 2006
Mitochondrial DNA Polymerase-y and Human Disease
Hum Mol Genet 15:R244-R252, Hudson, G.,et al, 2006
Migraine--Current Understanding and Treatment
NEJM 346:257-270, Goadsby,P.J.,et al, 2002
Features of Medication Overuse Headache Following Overuse of Different Acute Headache Drugs
Neurol 59:1011-1014,972, Limmroth,V.,et al, 2002
Ischemic Colitis and Sumatriptan Use
Arch Int Med 158:1946-1948, Knudsen,J.F.,et al, 1998
Butorphanol (Stadol) :A Study in Problems of Current Drug Information and Control
Neurol 48:1156-1160, Fisher,M.A.&Glass,S., 1997
Analgesic Headache
BMJ 310:479-480, Olesen,J., 1995
Valve Disease Associated with Ergot Alkaloid Use:Echocardiographic and Pathologic Correlations
Ann Int Med 117:50-52, Redfield,M.M.,et al, 1992
Abrupt Outpatient Withdrawal of Medication in Analgesic-Abusing Migraineurs
Lancet 337:1442-1443, Hering,T.&Steiner,T.J., 1991
Cocaine-Related Vascular Headahces
JNNP 54:803-806, Dhuna,A.,et al, 1991
Ergotamine Headache Mistaken for Temporal Arteritis
Ann Neurol 28:396, Winterkorn,J.M.S.,et al, 1990
Migrainelike Headache and Cocaine use
JAMA 261:2995-2996, Satel,S.L.&Gawin,F.H., 1989
Arterial Complications of Migraine Treatment with Methysergide & Parenteral Ergotamine
BMJ 285:260-261, Joyce,D.A.,et al, 1982
Dietary Migraine
Am Family Phys 3:176, Dalessio,D., 1972
Calcitonin Gene-Related Peptide-Targeted Therapy in Migraine: Current Role and Future Perspectives
Lancet 405:1014-1026, Versijpt,J.,et al, 2025
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine, A Phase 4, Randomized, Placebo-Controlled Trial
JAMA Neurol 81:1140-1149, Tepper,S.J.,et al, 2024
Genetic Causes of Cerebral Small Vessel Diseases, A Parctical Guide for Neurologists
Neurol 100:766-783, Manini,A.,&Pantoni,L., 2023
Atogepant for the Preventive Treatment of Chronic Migraine (PROGRESS): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial
Lancet 402:775-785, Pozo-Rosich,P.,et al, 2023
Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021
Atogepant for the Preventive Treatment of Migraine
NEJM 385:695-706, Ailani,J.,et al, 2021
Burning Pain in the Legs
NEJM 383:e18, Sacks, C.A., 2020
Encephalopathy in a Large Cohort of British Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy Patients
Stroke 50:283-290, Drazyk, A.M.,et al, 2019
A Woman in her 40s with Transient Neurological Symptoms, Migraine Headaches, and Hearing Loss
JAMA Neurol 76:504-505, Roshal, D.A.,et al, 2019
Antiepileptic Drug Treatment Patterns in Women of Childbearing Age with Epilepsy
JAMA Neurol 76:783-790, Kim, H.,et al, 2019
Remigepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine
NEJM 381:142-149, Lipton, R.B.,et al, 2019
Vestibular Migraine
BMJ 366:L4213, Li, V.,et al, 2019
Fremanezumab versus Placebo for Migraine Prevention in Patients with Documented Failure to Up to Four Migraine Preventive Medication Classes (FOCUS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3� Trial
Lancet 394:1030-1040, Ferrari, M.D.,et al, 2019
Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019
Ubrogepant for the Treatment of Migraine
NEJM 381:2230-2241, Dodick, D.W.,et al, 2019
Noninvasive Vagus Nerve Stimulation as Acute Therapy for Migraine
Neurol 91:e364-e373, Tassorelli,C., et al, 2018
Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018
Galcanezumab in Chronic Migraine
Neurol 91:e2211-e2221, Detke, H.C.,et al, 2018
Lasmiditan is an Effective Acute Treatment for Migraine
Neurol 91:e2222-e2232, Kuca, B.,et al, 2018
Clinicopathologic Conference, MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke like episodes)
NEJM 376:1668-1678, CASE 13-2017, 2017
CGRP - The Next Frontier for Migraine
NEJM 377:2190-2191, Hershey, A.D., 2017